LXRX Earnings & Financial Statements
Lexicon Pharmaceuticals, Inc.
$1.67
+$0.06(+4.06%)
38
Overall
60
Value
9
Tech
47
Quality
Market Cap
$711.93M
Volume
267.55K
52W Range
$1.10 - $2.68
Target Price
$4.55
LXRX earnings and financial statements: Lexicon Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
LXRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $49.80M | $31.08M | $1.20M | $139.0K | $298.0K |
| Cost of revenue | $274.0K | $616.0K | $85.0K | - | - |
| Operating income | -$48.91M | -$197.12M | -$171.75M | -$100.76M | -$87.09M |
| EBITDA | -$47.83M | -$195.10M | -$179.51M | -$98.00M | -$86.66M |
| Net income | -$50.34M | -$200.40M | -$177.12M | -$101.94M | -$87.76M |
| EPS (diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $184.99M | $298.42M | $229.43M | $194.30M | $136.91M |
| Total liabilities | $77.45M | $152.47M | $136.32M | $77.17M | $23.31M |
| Shareholders’ equity | $107.54M | $145.95M | $93.11M | $117.12M | $113.59M |
| Cash and equivalents | $34.33M | $66.66M | $22.46M | $46.34M | $64.06M |
| Long-term debt | $49.41M | $100.30M | $104.77M | $53.98M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$67.85M | -$178.78M | -$161.90M | -$88.85M | -$87.02M |
| Capital expenditure | - | -$1.03M | -$470.0K | -$1.33M | -$1.22M |
| Free cash flow | -$67.85M | -$179.81M | -$162.37M | -$90.18M | -$88.24M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LXRX | $1.67 | +4.1% | 267.55K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Lexicon Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW